Skip to main content

Table 1 Baseline pathological and clinical characteristics of patients

From: Neoadjuvant chemoradiotherapy for patients with unresectable radically locally advanced colon cancer: a potential improvement to overall survival and decrease to multivisceral resection

  No. (%)
Age, median, years 54 (43–63)
≤65 84 (84.0%)
> 65 16 (16.0%)
Sex
Male 73 (73.0%)
Female 27 (27.0%)
KPS
90 78 (78.0%)
80 22 (22.0%)
BMI, median, 21.4 (19.5–23.6)
Primary tumor length, median, cm 7.4 (1.7–8.9)
Primary tumor location
Sigmoid colon 60 (60.0%)
Descending colon 3 (3.0%)
Transverse colon 10 (10.0%)
Ascending colon 25 (25.0%)
Ileocecus 2 (2.0%)
Tumor differentiation
High 20 (20.0%)
Moderate 65 (65.0%)
Low 15 (15.0%)
CEA pre-CRT, median, ng/ml 6.1 (3.0–21.3)
Complication
No 56 (56.0%)
Yes 44 (44.0%)
cT stage
T3 4 (4.0%)
T4a 12 (12.0%)
T4b 84 (84.0%)
cN stage
N0 1 (1.0%)
N1 36 (36.0%)
N2 63 (63.0%)
Clinical stage
IIC 1 (1.0%)
IIIB 16 (16.0%)
IIIC 83 (83.0%)
Involved organ
Bladder 42 (42.0%)
Ureter 12 (12.0%)
Renal and perirenal fat, prerenal space 6 (6.0%)
Pelvic wall 10 (10.0%)
Presacral space 2 (2.0%)
Abdominal wall 11 (11.0%)
Mesentery 2 (2.0%)
Great vessel 8 (8.0%)
Small intestine 26 (26.0%)
Greater omentum 5 (5.0%)
Gallbladder 6 (6.0%)
Liver 9 (9.0%)
Appendix 1 (1.0%)
Pancreas 2 (2.0%)
Uterus 6 (6.0%)
Vagina 1 (1.0%)
Seminal vesicle gland 3 (3.0%)
Vas deferens 2 (2.0%)
Iliopsoas muscle 1 (1.0%)
Bladder fistula/perforation
Yes 14 (14.0%)
No 86 (86.0%)
Intestinal obstruction
Yes 19 (19.0%)
No 81 (81.0%)
Family history
Yes 20 (20.0%)
No 80 (80.0%)
Charlson Comorbidity Score
0 82 (82.0%)
1 15 (15.0%)
2 2 (2.0%)
3 1 (1.0%)
MMR
dMMR 14 (22.6%)
pMMR 48 (77.4%)
Unknown 38
  1. Abbreviations: KPS Karnofsky Performance Status, BMI Body Mass Index, cT stage Clinical T stage, cN stage Clinical N stage, MMR Mismatch repair phenotype